MacroGenics, Inc. - Common Stock (NQ: MGNX )
2.940
+0.080
(+2.80%)
Streaming Delayed Price
Updated: 3:34 PM EST, Feb 19, 2025
Add to My Watchlist
All News about MacroGenics, Inc. - Common Stock
![](https://mms.businesswire.com/media/20240802111527/en/779279/5/Screen_Shot_2020-03-10_at_10.22.21_AM.jpg)
![](https://mms.businesswire.com/media/20240802832453/en/805853/22/Robbins_LLP.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/07/31/Indian-Male-Serious-Doctor-Medical-Worke.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/60f84371-8ef5-454a-ab60-63e56a837741/small/schall-firm-logo-2-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2019/07/MTCH1600.jpg)
![](https://investorplace.com/wp-content/uploads/2022/02/cancer.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/07/31/xrdDAFej5iKviI3-j1743093025-t23032907.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-washington-statue.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/07/31/AMD-Ryzen.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/f6c754ad-b344-4389-a551-cf97ce05752e/small/robbins-llp-logo-white-background1583450-1-png.png)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://mms.businesswire.com/media/20240730822359/en/1510725/22/Latest_KSF_SEC.jpg)
![](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024
From MacroGenics, Inc.
Via GlobeNewswire
![](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)
![](https://mms.businesswire.com/media/20240729026788/en/2201211/22/new_KM_logo.jpg)
![](https://mms.businesswire.com/media/20240729565100/en/1138077/5/RGRD_Logo_BusinessWire.jpg)
![](https://mms.businesswire.com/media/20240729286815/en/827144/22/Schall-Firm-Logo-640x360.jpg)
![](https://ml.globenewswire.com/media/5d514042-8326-4555-8ad7-f6cc765ecfcd/small/bl-new-logo-jpg.jpg)
![](https://mms.businesswire.com/media/20240729527229/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/07/26/Image30.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)
From MacroGenics, Inc.
Via GlobeNewswire
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600c.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/06/03/Movers_0.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://mms.businesswire.com/media/20240513648859/en/774509/22/new_KM_logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)
From MacroGenics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.